| abstract |
The invention relates to the technical field of platelets, in particular to a platelet treatment guidance method based on drug gene polymorphism and thromboelastogram, which comprises the following steps: s1, detecting drug genes; s2, sequencing whole blood genome DNA; s3, carrying out metabolic type classification; s4, detecting TEG; s5, result analysis shows that the risk of new stroke within 90d can be effectively reduced without increasing the bleeding risk by guiding the treatment of the light ischemic stroke antiplatelet according to the drug gene polymorphism and the TEG. The gene detection and TEG can find patients insensitive to the treatment of the antiplatelet drugs in time, can provide a new basis for the selection of the antiplatelet drugs, so that the patients with ischemic stroke can select the antiplatelet drugs more accurately and reasonably, thereby formulating an individualized antiplatelet treatment scheme, effectively reducing the risk of stroke recurrence, having important guiding significance for the secondary prevention of ischemic stroke, and being worthy of clinical popularization and application. |